This is WHAT we do…  We advance basic knowledge of blood coagulation so that new and much-needed anticoagulant medicines can be designed and developed using structure-based principles.

This is WHY we do it…  Despite current treatments, blood clots remain a massive global health issue, affecting as many as 900,000 people each year and causing approximately 100,000 premature deaths in the U.S. alone.  Why anticoagulation fails in so many individuals is unknown, reflecting our incomplete understanding of how coagulation works and the need for personalized treatments. 

This is HOW we do it…  Our main research focus is Antiphospholipid Syndrome (APS), an autoimmune disorder that causes unexpected and life-threatening blood clots. There is no cure for APS, diagnosis remains challenging, and treatment is suboptimal.   Our approach to solving APS is rooted in rigorous structural and mechanistic biochemistry.  We study antigen–antibody interactions, investigate new targets to lower thrombotic risk, and develop monoclonal antibodies and nanobodies as advanced research tools and potential therapeutics.  WE ARE HUNTERS. And we are going for APS !!!